Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Up 0.2 %

NASDAQ SUPN opened at $30.76 on Thursday. Supernus Pharmaceuticals has a 52 week low of $25.53 and a 52 week high of $40.28. The company has a 50 day moving average price of $32.76 and a 200 day moving average price of $35.01. The firm has a market cap of $1.72 billion, a PE ratio of 28.75 and a beta of 0.90.

Insider Activity

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock worth $440,263 over the last 90 days. 9.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. QRG Capital Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 5.5% in the first quarter. QRG Capital Management Inc. now owns 17,583 shares of the specialty pharmaceutical company’s stock valued at $576,000 after purchasing an additional 913 shares during the period. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 12.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 24,881 shares of the specialty pharmaceutical company’s stock worth $815,000 after buying an additional 2,762 shares during the period. Azzad Asset Management Inc. ADV acquired a new stake in Supernus Pharmaceuticals during the 1st quarter valued at approximately $552,000. SG Americas Securities LLC boosted its holdings in shares of Supernus Pharmaceuticals by 63.6% in the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company’s stock valued at $579,000 after acquiring an additional 6,867 shares during the last quarter. Finally, Wedge Capital Management L L P NC increased its stake in shares of Supernus Pharmaceuticals by 26.2% in the first quarter. Wedge Capital Management L L P NC now owns 67,286 shares of the specialty pharmaceutical company’s stock worth $2,204,000 after acquiring an additional 13,955 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.